- Home
- PIII vs LGVN Comparison
PIII vs LGVN Comparison
Compare PIII & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | LGVN |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 11.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PIII | LGVN |
|---|---|---|
| Price | $2.14 | $0.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $16.25 | $6.50 |
| AVG Volume (30 Days) | 111.2K | ★ 143.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.85 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.15 | $0.49 |
| 52 Week High | $11.30 | $1.92 |
Technical Indicators
Market Signals| Indicator | PIII | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 52.96 |
| Support Level | $1.96 | $0.52 |
| Resistance Level | $2.85 | $0.57 |
| Average True Range (ATR) | 0.33 | 0.03 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 46.24 | 96.44 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.